Item Type | Name |
Concept
|
Acute Disease
|
Concept
|
Cardiovascular Diseases
|
Concept
|
Chronic Disease
|
Concept
|
Kidney Diseases
|
Concept
|
Liver Diseases, Alcoholic
|
Concept
|
Metabolic Diseases
|
Concept
|
Urologic Diseases
|
Concept
|
Disease Management
|
Concept
|
Disease Progression
|
Concept
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
|
Concept
|
End Stage Liver Disease
|
Concept
|
Disease Models, Animal
|
Concept
|
Liver Diseases
|
Concept
|
Disease-Free Survival
|
Concept
|
Genetic Predisposition to Disease
|
Academic Article
|
Protein metabolism and liver disease.
|
Academic Article
|
Natural history and management of hepatitis C infection after liver transplantation.
|
Academic Article
|
Fibrosing NASH: on being a blind man in a dark room looking for a black cat (that isn't there).
|
Academic Article
|
Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels.
|
Academic Article
|
Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease?
|
Academic Article
|
Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.
|
Academic Article
|
Liver transplantation for cryptogenic cirrhosis.
|
Academic Article
|
Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease.
|
Academic Article
|
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
|
Academic Article
|
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
|
Academic Article
|
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation.
|
Academic Article
|
Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives.
|
Academic Article
|
Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases.
|
Academic Article
|
Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant.
|
Academic Article
|
Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation.
|
Academic Article
|
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice.
|
Academic Article
|
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
|
Academic Article
|
The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database.
|
Academic Article
|
Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
|
Academic Article
|
Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?
|
Academic Article
|
Hepatocyte tails.
|
Academic Article
|
Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.
|
Academic Article
|
Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
|
Academic Article
|
Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease.
|
Academic Article
|
Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.
|
Academic Article
|
Branched-chain amino acid enriched supplements as therapy for liver disease.
|
Academic Article
|
Approach to recurrent hepatitis C following liver transplantation.
|
Academic Article
|
Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain?
|
Academic Article
|
Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
|
Academic Article
|
A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA.
|
Academic Article
|
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.
|
Academic Article
|
Introduction to the genetics and biology of interleukin-28B.
|
Academic Article
|
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
|
Academic Article
|
Nutrition in alcoholic liver disease.
|
Academic Article
|
Impact of obesity on treatment of chronic hepatitis C.
|
Academic Article
|
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.
|
Academic Article
|
Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease.
|
Academic Article
|
NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery--a prospective analysis.
|
Academic Article
|
Posttransplant metabolic syndrome: new evidence of an epidemic and recommendations for management.
|
Academic Article
|
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
|
Academic Article
|
Chronic kidney disease (CKD) and NAFLD: time for awareness and screening.
|
Academic Article
|
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
|
Academic Article
|
Obesity is independently associated with infection in hospitalised patients with end-stage liver disease.
|
Academic Article
|
Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease.
|
Academic Article
|
Daclizumab induction therapy in liver transplant recipients with renal insufficiency.
|
Academic Article
|
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.
|
Academic Article
|
Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD.
|
Academic Article
|
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
|
Academic Article
|
Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease.
|
Academic Article
|
Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery.
|
Academic Article
|
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
|
Academic Article
|
The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States.
|
Academic Article
|
The impact of gender and NASH on chronic kidney disease before and after liver transplantation.
|
Academic Article
|
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.
|
Academic Article
|
Nonalcoholic fatty liver disease: a review of current understanding and future impact.
|
Academic Article
|
Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.
|
Academic Article
|
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
|
Academic Article
|
Evolving aspects of liver transplantation for nonalcoholic steatohepatitis.
|
Academic Article
|
Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events.
|
Academic Article
|
Metabolic syndrome and liver transplantation: a review and guide to management.
|
Academic Article
|
Pretransplant serum troponin levels are highly predictive of patient and graft survival following liver transplantation.
|
Academic Article
|
Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient.
|
Academic Article
|
Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management.
|
Academic Article
|
Nonalcoholic Fatty Liver Disease and Liver Transplantation.
|
Academic Article
|
Alcoholic Liver Disease and Liver Transplantation.
|
Academic Article
|
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health.
|
Academic Article
|
Usefulness of Liver Transplantation in the Elderly: The Converging Impact of Risk and Benefit.
|
Academic Article
|
Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.
|
Academic Article
|
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
|
Academic Article
|
Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.
|
Academic Article
|
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
|
Academic Article
|
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
|
Academic Article
|
Predictors of Cardiovascular Events After Liver Transplantation.
|
Academic Article
|
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
|
Academic Article
|
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
|
Academic Article
|
Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study.
|
Academic Article
|
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
|
Academic Article
|
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.
|
Academic Article
|
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
|
Academic Article
|
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
|
Academic Article
|
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
|
Academic Article
|
International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation.
|
Academic Article
|
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
|
Academic Article
|
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
|
Academic Article
|
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
|
Academic Article
|
Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts.
|
Academic Article
|
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
|
Academic Article
|
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients.
|
Academic Article
|
FGF-19 agonism for NASH: a short study of a long disease.
|
Academic Article
|
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
|
Academic Article
|
The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis.
|
Academic Article
|
Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era.
|
Academic Article
|
Nonalcoholic Steatohepatitis After Liver Transplantation.
|
Academic Article
|
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
|
Academic Article
|
Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system.
|
Academic Article
|
Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency.
|
Academic Article
|
Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes.
|
Academic Article
|
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
|
Academic Article
|
Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
|
Academic Article
|
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers.
|
Academic Article
|
Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs.
|
Academic Article
|
The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes.
|
Academic Article
|
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
|
Academic Article
|
Relatively Poor Long-term Outcomes Following Liver Transplantation for NASH in the United States.
|
Academic Article
|
Imbalanced gut microbiota predicts and drives the progression of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in a fast-food diet mouse model.
|
Concept
|
Non-alcoholic Fatty Liver Disease
|
Grant
|
REDUCTION OF HCV RECURRANCE AFTER LIVER TRANSPLANTATION
|
Grant
|
Pathophysiology and Characterisation of NAFLD
|
Academic Article
|
Liver Transplantation 2023: Status Report, Current and Future Challenges.
|
Academic Article
|
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
|
Academic Article
|
Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
|
Academic Article
|
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
|
Academic Article
|
SARS-CoV-2 Disease Severity in the Golden Syrian Hamster Model of Infection Is Related to the Volume of Intranasal Inoculum.
|
Academic Article
|
Macrophage RAGE activation is proinflammatory in NASH.
|
Academic Article
|
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
|
Academic Article
|
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
|